Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
The ERR gene lacks the typical TATA
2021-07-02

The ERRα gene lacks the typical TATA and CAAT boxes, but has multiple consensus Sp1 binding elements in the GC-rich promoter (Shi et al., 1997). Previously, our laboratory has shown that ERRα expression is upregulated in the mouse uterus by estrogen (Shigeta et al., 1997) and recently we identified
-
Drug resistance to both pathogens and
2021-07-02

Drug resistance to both pathogens and cancer has been a big hindrance in healthcare. Integrated research undertakings are being pursued to find the exact causes of the lack of response towards drugs. Surprisingly, host pumps are the key factors in failure of most drugs. The pumps either do not allow
-
The Liver X Receptor and LXRs NR H and
2021-07-02

The Liver X Receptor-α and -β (LXRs, NR1H3 and NR1H2, respectively) are members of the nuclear receptor superfamily that play a central role in controlling cholesterol homeostasis [9], [10]. In macrophages, LXRs can decrease the cellular sterol burden by inducing expression of the cholesterol efflux
-
The field of synthetic cytokine
2021-06-29

The field of synthetic cytokine biology continues to grow through molecular, physiological and pathophysiological insights, as well as via new methodical advances. The approval of chimeric antigen receptor (CAR) T cell immunotherapy by the US Food and Drug administration (FDA) in August 2017 for rel
-
br Materials and methods br Results
2021-06-29

Materials and methods Results and discussion Conclusions Conflict of interest Acknowledgments This work was financially supported by the National Natural Science Foundation of China (31302162, 31171762), National High Technology Research and Development Program of China (863 Program,
-
Previous studies have shown the harmful effects
2021-06-29

Previous studies have shown the harmful effects of NEFA on ovarian functionality, such as inhibition of bovine granulosa cell survival and proliferation, steroidogenesis, and follicular development and alteration in oocyte development [36,45,46]. Therefore, the higher levels of NEFA found in the fol
-
Secondary and primary studies have considered the decision t
2021-06-29

Secondary and primary studies have considered the decision to select the provider and to select components after the component origin is chosen. Examples of secondary and primary studies outside our scope, but still related to decision-making are listed in Tables 1 and 2. The secondary and primary s
-
The ESC update emphasizes the need
2021-06-28

The 2017 ESC update emphasizes the need for implementing strategies to minimize PCI-related complications, including risk stratification for ischemia and bleeding, keeping triple antithrombotic therapy to the shortest possible duration with dual antithrombotic therapy as an alternative, using non–vi
-
In conclusion substrate enabled effective detection of
2021-06-28

In conclusion, substrate enabled effective detection of L-alanylaminopeptidase activity in all Gram-negative bacteria tested here. The chromogenic substrate showed high sensitivity at a relatively low concentration (50 mgL), with no diffusion of the coloured chelate into the surrounding agar. Lack o
-
Potential break through technology poised
2021-06-28

Potential break-through technology poised to overcome these above-mentioned limitations is that of the “substrate mediated enzyme prodrug therapy”, SMEPT (Fig. 1). Learning from the previously established enzyme prodrug therapies (EPT) and specifically the antibody-directed EPT (ADEPT) [12], develop
-
br Clinical potential of ET receptor biased ligands Is there
2021-06-28

Clinical potential of ET receptor biased ligands Is there a clinical need for ET receptor biased ligands? Evidence is strongest from research in epithelial ovarian cancer demonstrating that ET-1 stimulated ETA-mediated β-arrestin signalling leads to activation of the oncogenic mediator NF-κB [21]
-
br Mass spectrometry based technologies Oxysterols tend
2021-06-28

Mass spectrometry-based technologies Oxysterols tend not to be observed in global lipidomic analysis, whether shot-gun based electrospray ionisation – mass spectrometry (ESI-MS) or liquid chromatography (LC)-MS based. This is because of their comparatively low-abundance and poor ionisation charac
-
The present study provides the
2021-06-28

The present study provides the first evidence that the human uroepithelial PCI-34051 mg in vitro respond directly, within 48h, to this carcinogen by promoting extensive vacuolation and DAPK expression. By using the TEM, ICC and Western blotting, we found that the arsenite-induced vacuoles were deri
-
br Materials and methods br Results Metabolic stability of c
2021-06-28

Materials and methods Results Metabolic stability of compounds was studied by incubation with pooled human liver microsomes. Piperine was the metabolically most stable compound, with a t1/2 of 141min (Fig. 2, and Table 1). SCT-29 and LAU 397 showed t1/2 of approx. 45min, whereas a t1/2 of only
-
Although differences in several nociceptive tests have previ
2021-06-28

Although, differences in several nociceptive tests have previously been described across strains (Mogil et al., 1999), it is the first time that pain sensitivity in response to chemical and thermal stimuli has been evaluated in B6,129CRHtklee mice. Our results showed no differences in pain sensitivi
14393 records 598/960 page Previous Next First page 上5页 596597598599600 下5页 Last page